ProCE Banner Activity

Expert Insights on Key Updates From the 2022 ESMO Congress on PARP Inhibitors in Ovarian Cancer

Podcast Episodes
In this podcast episode, listen to Domenica Lorusso, MD, PhD, and Alexandra Leary, MD, PhD, discuss key updates for PARP inhibitor trials in ovarian cancer presented at the 2022 ESMO Congress, including the 7-year update from SOLO-1, final OS analyses for PAOLA-1, disease risk subgroup analysis from ATHENA-MONO, and OS results from ARIEL4.

Released: October 04, 2022

Expiration: October 03, 2023

No longer available for credit.

Share

Faculty

Alexandra Leary

Alexandra Leary, MD, PhD

Co director
Medical Oncologist and Team Leader
Gynecology Translational Research Lab
Department of Medicine
Gustave Roussy Cancer Center
Paris, France

Domenica Lorusso

Domenica Lorusso, MD, PhD

Associate Professor 
Catholic University of Sacred Heart
Haear of Clinical Research Development Unit
Fondazione Policlinico Gemelli IRCCS
Rome, Italy

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

GlaxoSmithKline

Karyopharm Therapeutics Inc.

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Alexandra Leary, MD, PhD

Co director
Medical Oncologist and Team Leader
Gynecology Translational Research Lab
Department of Medicine
Gustave Roussy Cancer Center
Paris, France

Alexandra Leary, MD, PhD, has disclosed that she has received funds for research support from Ability, AstraZeneca, Clovis, GlaxoSmithKline, MSD, and Tesaro; consulting fees from Ability, AstraZeneca, Biocad, Clovis, Merck Serono (paid to her institution), MSD, Seattle Genetics, Tesaro, and Zentalis; and other financial or material support from AstraZeneca, Clovis, GlaxoSmithKline, and Tesaro.

Domenica Lorusso, MD, PhD

Associate Professor 
Catholic University of Sacred Heart
Haear of Clinical Research Development Unit
Fondazione Policlinico Gemelli IRCCS
Rome, Italy

Domenica Lorusso, MD, PhD, has disclosed that she has received consulting fees from Amgen, AstraZeneca, Clovis, GlaxoSmithKline, MSD, and Pharmamar; fees for non-CME/CE services from MSD; and other financial or material support from AstraZeneca, Clovis, GlaxoSmithKline, and Pharmamar.